Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505

Author:

Kitagawa Ryo1,Katsumata Noriyuki1,Shibata Taro1,Kamura Toshiharu1,Kasamatsu Takahiro1,Nakanishi Toru1,Nishimura Sadako1,Ushijima Kimio1,Takano Masashi1,Satoh Toyomi1,Yoshikawa Hiroyuki1

Affiliation:

1. Ryo Kitagawa, NTT Medical Center Tokyo; Taro Shibata, National Cancer Center; Takahiro Kasamatsu, National Cancer Center Hospital, Tokyo; Noriyuki Katsumata, Nippon Medical School, Musashikosugi Hospital, Kanagawa; Toshiharu Kamura and Kimio Ushijima, Kurume University, Fukuoka; Toru Nakanishi, Aichi Cancer Center Hospital, Aichi; Sadako Nishimura, Osaka City General Hospital, Osaka; Masashi Takano, National Defense Medical College, Saitama; and Toyomi Satoh and Hiroyuki Yoshikawa, University of Tsukuba,...

Abstract

Purpose In metastatic or recurrent cervical cancer, cisplatin-based chemotherapy is standard. The JCOG0505 randomized phase III trial evaluated the clinical benefits of carboplatin-based regimen. Patients and Methods Eligible patients had metastatic or recurrent cervical cancer and had ≤ one platinum-containing treatment and no prior taxane. Patients were randomly assigned either to conventional paclitaxel plus cisplatin (TP; paclitaxel 135 mg/m2 over 24 hours on day 1 and cisplatin 50 mg/m2 on day 2, repeated every 3 weeks) or paclitaxel plus carboplatin (TC; paclitaxel 175 mg/m2 over 3 hours and carboplatin area under curve 5 mg/mL/min on day 1, repeated every 3 weeks). Primary end point was overall survival (OS). Planned sample size was 250 patients to confirm the noninferiority of TC versus TP with the threshold hazard ratio (HR) of 1.29. Results Between February 2006 and November 2009, 253 patients were enrolled. The HR of OS was 0.994 (90% CI, 0.79 to 1.25; noninferiority P = .032 by stratified Cox regression). Median OS was 18.3 months with TP versus 17.5 months with TC. Among patients who had not received prior cisplatin, OS was shorter with TC (13.0 v 23.2 months; HR, 1.571; 95% CI, 1.06 to 2.32). One treatment-related death occurred with TC. Proportion of nonhospitalization periods was significantly longer with TC (P < .001). Conclusion TC was noninferior to TP and should be a standard treatment option for metastatic or recurrent cervical cancer. However, cisplatin is still the key drug for patients who have not received platinum agents.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3